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The inner ear develops from an ectodermal placode that is specified by inductive signals from the adjacent neurectoderm and underlying
mesoderm. In chick, fibroblast growth factor (Fgf)-19 is expressed in mesoderm underlying the presumptive otic placode, and human FGF19
induces expression of otic markers in a tissue explant containing neural plate and surface ectoderm. We show here that mouse Fgf15 is the
sequence homolog of chick and human Fgf19/FGF19. In addition, we show that FGF15, like FGF19, is sufficient to induce expression of
otic markers in a chick explant assay, suggesting that these FGFs are orthologs. Mouse embryos lacking Fgf15, however, do not have otic
abnormalities at E9.5–E10.5, suggesting that Fgf15 is not uniquely required for otic induction or early patterning of the otocyst. To compare
FGF15 and FGF19 signaling components and assess where signals potentially redundant with FGF15 might function, we determined the
expression patterns of Fgf15 and Fgf19. Unlike Fgf19, Fgf15 is not expressed in mesoderm underlying the presumptive otic placode, but is
expressed in the adjacent neurectoderm. Fgfr4, which encodes the likely receptor for both FGF19 and FGF15, is expressed in the
neurectoderm of both species, and is also expressed in the mesoderm only in chick. These results suggest the hypotheses that during otic
induction, FGF19 signals in either an autocrine fashion to the mesoderm or a paracrine fashion to the neurectoderm, whereas FGF15 signals
in an autocrine fashion to the neurectoderm. Thus, the FGFs that signal to the neurectoderm are the best potential candidates for redundancy
with FGF15 during mouse otic development.
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Introduction mesoderm (Baker and Bronner-Fraser, 2001; Groves,The inner ear contains the sensory organs specialized for
audition and balance. This complex structure develops from
a simple ectodermal placode that forms adjacent to the
developing hindbrain. The preplacodal tissue is specified
and subsequently committed to an otic fate by inductive
signals from the adjacent neurectoderm and underlying0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2004.02.003
* Corresponding author. Department of Human Genetics, University of
Utah, 15 North 2030 East, Room 2100, Salt Lake City, UT 84112-5330.
Fax: +1-801-581-7796.
E-mail address: suzi.mansour@genetics.utah.edu (S.L. Mansour).
1 These authors contributed equally to this work.
2 Present address: Alexion Antibody Technologies Inc., 3985 Sorrento
Valley Boulevard. Suite A, San Diego, CA 92121, USA.2004; Kiernan et al., 2002; Ladher et al., 2000). In chick,
the otic placode is specified at the 4–5-somite stage
[Hamburger–Hamilton (HH) 8 to 8+] and committed by
the 9–10-somite stage (HH10 to 10), as assayed by
expression of Pax2 (Groves and Bronner-Fraser, 2000;
Hamburger and Hamilton, 1992). The otic placode is visible
morphologically as a region of thickened ectoderm by the 7-
somite stage (HH9) (Alvarez and Navascues, 1990). Exper-
imental embryological studies of the timing of specification
and commitment of the otic placode have not been carried
out in the mouse. Morphological observations, however,
suggest that the mouse otic placode thickens lateral to
rhombomeres 5 and 6 at the 7–8-somite stage (Wright
and Mansour, 2003a,b). In both chick and mouse, the
thickened placode subsequently invaginates and forms a
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tion and morphogenesis, which ultimately results in forma-
tion of the inner ear. Several intercellular signaling
molecules, including the fibroblast growth factors (FGFs),
are involved in each of these processes (Kiernan et al., 2002;
Mansour and Schoenwolf, 2004; Riley and Phillips, 2003;
Wright and Mansour, 2003b).
Recently, the role of FGFs in induction of the inner ear in
mice, chick, and zebrafish has been the subject of extensive
study (Ladher et al., 2000; Leger and Brand, 2002; Maroon
et al., 2002; Phillips et al., 2001; Wright and Mansour,
2003a). Simultaneous depletion of FGF3 and FGF8 in
zebrafish, by using combinations of Fgf3 and Fgf8 mor-
pholinos or by injection of Fgf3 morpholinos into ace
(Fgf8) mutant embryos, leads to alterations in gene expres-
sion patterns in the placode and to a severe reduction in the
size of the otic vesicle (Leger and Brand, 2002; Maroon et
al., 2002; Phillips et al., 2001). Therefore, Fgf3 and Fgf8,
which are both expressed in hindbrain rhombomere 4, are
required redundantly for otic induction in this species. As
the otic defects are accompanied by severe abnormalities in
hindbrain patterning, however, it is not clear whether these
defects are caused by loss of FGF signals acting directly on
preplacodal otic ectoderm, or by disruption of other otic-
inducing signals from the hindbrain (Maves et al., 2002;
Walshe et al., 2002). In mouse, Fgf3/Fgf10 double-homo-
zygous mutant embryos lack otic vesicles, but these embry-
os do not show abnormalities of hindbrain patterning,
suggesting that neurectodermal Fgf3 and mesenchymal
Fgf10 are required redundantly for otic induction and that
they act directly on the otic ectoderm (Alvarez et al., 2003;
Wright and Mansour, 2003a). In chick, mesodermal Fgf19
and neurectodermal Wnt8c have the spatial and temporal
expression profiles appropriate for otic inducers. Applica-
tion of both gene products, but neither alone, to uncommit-
ted prospective otic ectoderm is sufficient to induce otic
marker gene expression, suggesting that Fgf19 and Wnt8c
act in concert to initiate otic development (Ladher et al.,
2000). FGF19 can also initiate otic gene expression by itself
when the responding ectoderm also contains neural plate,
presumably because the neurectoderm provides a requisite
WNT signal (Chapman et al., 2004).
We show here, based on amino acid sequence similarity
as well as mouse/human synteny, that mouse Fgf15 is the
homolog of chick and human FGF19. Fgf15 was initially
identified as a direct target of the homeodomain oncoprotein
E2A-PBX1, and it is expressed extensively in the develop-
ing nervous system (Ford-Perriss et al., 2001; Gimeno et al.,
2002, 2003; McWhirter et al., 1997). Chick explant experi-
ments show that FGF15 is able to induce expression of otic
markers, similarly to FGF19. Fgf15-deficient mouse embry-
os, however, have normal otic vesicles, suggesting that if
Fgf15 plays a role in mouse otic induction or early pattern-
ing, its function must be redundant. Furthermore, a com-
parison of the early expression patterns of mouse Fgf15 and
chick Fgf19 reveals additional insights into how the roles ofthese orthologs may differ during mouse and chick otic
induction. Most notably, mouse Fgf15 is never expressed in
the mesenchyme underlying the preplacodal ectoderm, but it
is found instead in the neurectoderm during the earliest
phases of otic induction and subsequently in the surface
ectoderm ventral to the otic placode. In contrast, in addition
to its early expression in the mesoderm underlying the
preplacodal ectoderm, chick Fgf19 expression in the neu-
rectoderm is initiated after the earliest phases of otic
induction and is not found in surface ectoderm. Finally,
comparisons of the expression pattern of Fgfr4, which
encodes the presumed receptor for FGF19 and FGF15
(Xie et al., 1999), are consistent with the idea that the roles
of Fgf15 and Fgf19 in otic induction may differ. Chick
Fgfr4 is expressed in both mesoderm and neurectoderm,
suggesting either autocrine or paracrine roles for Fgf19 in
chick otic induction. In contrast, mouse Fgfr4 is expressed
only in the neurectoderm (Wright et al., 2003), suggesting
that the role of Fgf15 in otic induction may be restricted to
this tissue. Taken together, these data are consistent with a
model in which there are both similarities and differences in
the identity and locations of the FGF signals that direct otic
development in different species.Materials and methods
Genomics
BLASTP analysis (http://www.ncbi.nlm.nih.gov/
BLAST/) of chicken FGF19 (GenBank accession number-
AAG39478) and human FGF19 (GenBank accession num-
ber NP_005108) was used to determine the closest relative
in the mouse genome. Protein alignments and phylogenetic
trees were produced using MegAlign, which is a component
of the Lasergene sequence analysis package (http://
www.dnastar.com). Schematic views of the human and
mouse genomes comprising the Fgf19/Fgf15 syntenic
regions were adapted from the human (NCBI build 34)
and mouse (NCBI build 30) ENSEMBL worldwide web
sites, respectively (http://www.ensembl.org/).
Otic induction in explant cultures
FGF19-coated beads were prepared as described previ-
ously (Ladher et al., 2000). To prepare cells expressing
Fgf15, a mouse Fgf15 cDNA containing the complete open
reading frame (McWhirter et al., 1997) was cloned into
pcDNA3.1 (Invitrogen). Two hundred ninety-three human
embryonic kidney cells were stably transfected with this
Fgf15 expression construct. After selection with Geneticin,
these cells were used as a source of FGF15. Assays of otic
induction employed stage 4/5 rostral chick epiblast, consist-
ing of both neural plate and surface ectoderm and stripped
of underlying mesendoderm, as the responding tissue. This
ectoderm was isolated and wrapped around FGF19 beads or
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sandwiches were placed into collagen gel drop culture and
assayed after one or 2 days for expression of Pax2 and
Nkx5.1 as described previously (Ladher et al., 2000). A
three-layered tissue block taken from the rostral region of a
stage 4/5 embryo and expressing the endogenous otic-
inducing signals served as an additional positive control.
Negative controls included rostral stripped ectoderm cul-
tured in the absence of additional factors, as well as explant
sandwiches combined with untransfected 293 cells.
Generation and analysis of Fgf15-deficient mice
A 1.53-kb Fgf15 cDNA probe was used to screen a
mouse 129/SvJ genomic library and the three exons of
Fgf15 were mapped and sequenced (McWhirter et al.,
1997). A 10.7 kb SacII–SalI genomic DNA fragment
containing the three Fgf15 exons was subcloned into the
phagemid vector pBluescript II SK(+). An internal 1.6 kb
XbaI to SnaBI fragment containing about 800 bp each of
intron 2 and exon 3 was replaced with an MC1-NeopA
expression cassette, which was oriented such that the
promoters for Neo and Fgf15 transcription were opposed.
The deleted region of exon 3 included sequences encoding
the C-terminal 52% of secreted FGF15, which carries 41%
of the FGF core homology, including a cysteine residue
that is 100% conserved among FGFs as well as the
majority of sequences expected to be involved in HSPG
and FGFR binding (McWhirter et al., 1997; Plotnikov et
al., 2000; Schlessinger et al., 2000). The resulting targeting
vector contained 2.4 and 6.7 kb of homology on the 5V and
3V arms, respectively. The linearized targeting vector was
electroporated into R1 mouse embryonic stem (ES) cells
(Nagy et al., 1993). Electroporated cells were cultured in
the presence of G418 sulfate (0.15 mg/ml). Correctly
targeted ES cell clones were identified by Southern blot
analysis using 5V and 3V probes that flanked the Fgf15
homology and EcoRV, XbaI, and XhoI as diagnostic
enzymes. ES cell clone Fgf15-B12 was expanded and
injected into C57Bl/6 blastocysts to obtain chimeric mice.
Male chimeras were mated with C57Bl/6 females to pro-
duce C57Bl/6/129/Sv hybrid F1 progeny carrying the
targeted Fgf15 allele.
Fgf15 heterozygous animals were intercrossed to generate
homozygous mutant, heterozygous and wild-type embryos.
Genotypes were determined using PCR amplification of yolk
sac or tail DNA (McMahon et al., 1990). Combined wild-
type and mutant PCR analysis was performed in 10
Al reactions amplified in an air thermal cycler (Idaho
Technologies) for 35 cycles with 0 s at 94jC, 0 s at 60jC
and 30 s at 72jC. The sequences of the primers were: 5V
primer (G1), 5V-CAAGGGAATATGGCTCCAGTCTG-3V; 3V
primer (G2), 5V-ATATCCACGCAGAAGCTGGCAGTG-3V;
Neo primer (G3), 5V-CGCCTTCTTGACGAGTTCTT-3V.
The wild-type PCR product was 500 bp and the mutant
PCR product was 370 bp.For RT-PCR analysis of embryonic transcripts, total RNA
was isolated from E12.5 wild-type, heterozygous, and ho-
mozygous mutant embryos using TRIzol (Life Technolo-
gies). The RNA was treated with DNAse I and first-strand
cDNAs were synthesized using random primers and Super-
script II reverse transcriptase (Life Technologies). The 3V
PCR primers were in exon 2 (R1) and the 3V region of exon 3
(R2), and amplified a 984-bp product from wild-type cDNA.
The 5V PCR primers were in exon 1 (R3) and exon 2 (R4),
and amplified a 166-bp product from wild-type cDNA. The
sequences of the primers were: R1: 5V-AGACATTGCCAT-
CAAGGAC-3V, R2: 5V-GGGACAGAGACAAGCTCCTG-
3V, R3: 5V-AAGATTACCCGCCTGCAGTA-3V and R4: 5V-
GTCCTTGATGGCAATCGTCT-3V. PCR analysis was
performed in 10-Al reactions amplified in an air thermal
cycler (Idaho Technologies) for 35 cycles with 0 s at 94jC, 0
s at 57jC, and 1 min at 72jC. PCR amplification using
primers located within the Hprt gene (5V-CCTGCTGGAT-
TACATTAAAGCACTG-3V and 5V-GTCAAGGGCATATC-
CAACAACAAAC-3V) was used as a control for RNA
quantity and quality.
Otic development was analyzed in Fgf15/ and control
embryos by paraffin sectioning followed by staining with
hematoxylin and eosin. In situ hybridization analysis of
Pax2 expression at E10.5 was performed according the
protocol described above using the probe described by
Dressler et al. (1990).
Whole-mount in situ hybridization and sectioning of
embryos
The expression pattern of Fgf15 was determined using
wild-type CD-1 (Charles River Laboratories) embryos iso-
lated from pregnant females on the indicated days following
detection of a vaginal plug. Chick embryos were obtained
by incubating fertilized hen’s eggs (Dunlap Hatchery, Cald-
well, ID, USA and Yamamoto Eggs, Kobe, Japan) in
humidified incubators at 38jC until they had reached the
required stages (Hamburger and Hamilton, 1992). Antisense
riboprobes labeled with digoxigenin were transcribed from
plasmids containing either mouse Fgf15 or chick Fgf19
cDNAs (Ladher et al., 2000; McWhirter et al., 1997). A
fragment of chick Fgfr4 was prepared by PCR amplification
of chick cDNA using the primers 5V-CAGCAGGTAGCTG-
TAGCG-3 V and 5 V-CAGCCAGACTCGCTGGC-3 V
corresponding to bp 103–479 of the C. coturnix FREK
mRNA (GenBank accession number: X76885.1; Marcelle et
al., 1994) and cloned into pBluescript II SK(+) for prepa-
ration of in situ hybridization probes. Chick embryos
younger than stage 18 and mouse embryos were hybridized
with species-specific riboprobes, which were detected as
described previously (Henrique et al., 1995). Fgf19 expres-
sion in chick embryos older than stage 18 was investigated
using a modified protocol. This differed in the hybridization
solution used and the post-hybridization washing regime
employed. The hybridization solution contained 50% form-
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Following hybridization, the embryos were washed twice at
65jC in 50% formamide, 2 SCC, and 1% SDS for 30 min
and twice with 50% formamide, 0.2 SCC, and 1% SDS for
30 min at 65jC. Following these post hybridization washes,
the protocol for all embryos was identical (Henrique et al.,
1995).
Embryos stained for analysis of gene expression were
sectioned for microscopic evaluation. Chick embryos that
had more than 14 somites and mouse embryos were cry-
oprotected in sucrose and sectioned at 14 Am using a Leica
cryostat (Stark et al., 2000). Chick embryos with fewer than
14 somites were embedded in gelatin and subsequently
sectioned at 40 Am using a Gillette razor blade and a Leica
vibratome (Karabagli et al., 2002).Fig. 1. Fgf15 is the mouse homolog of chick and human FGF19 and these
genes form part of a syntenic group that includes Fgf3 and Fgf4. (A)
Phylogenetic tree (above) and amino acid identity chart (below) illustrating
the relationships between the human (H. s.), mouse (M. m.), and chick (G.
g.) FGF3, FGF4, and FGF19/15 proteins. (B) Schematic depiction of the
order and direction of transcription of FGF/Fgf and flanking genes within a
syntenic region of human chromosome 11q13.3 (upper) and mouse
chromosome 7F5 (lower). The direction of transcription is indicated by
the direction of the arrow enclosing each gene name. Abbreviations: Tel,
telomere; Cen, centromere.Results
Fgf15 is the mouse homolog of chick and human Fgf19
FGF19 was shown to function as one of the signals
inducing otic development in chick (Ladher et al., 2000). To
identify the mouse homolog of chick and human FGF19, we
searched the protein databases with the FGF19 amino acid
sequence and aligned the closest matches as well as the
entire human, mouse, and available chick FGF family
members for comparison. We also utilized the available
genomic sequences for human and mouse to compare the
gene structure and context of human FGF19 with respect to
potential syntenic regions in the mouse. The database
searches and protein alignments revealed that the mouse
FGF most closely related to chick and human FGF19 had
already been named FGF15 (McWhirter et al., 1997), which
has 32% and 50% identity to chick and human FGF19,
respectively (Fig. 1A). This level of sequence conservation
is lower than that for any other set of mouse, human, and
chick homologs within the FGF family. For example, the
FGF3 proteins from the three species are 64–81% identical
and the FGF4 proteins are 70–80% identical in pairwise
comparisons (Fig. 1A). Nevertheless, the human FGF19
and the mouse Fgf15 genes occupy similar positions within
a syntenic cluster of three FGF genes, including FGF3/Fgf3
and FGF4/Fgf4, that are located on chromosomes 11q13.3
and 7F5, respectively (Fig. 1B) (Katoh, 2002). In both
species, the three FGF genes are oriented as head-to-tail
tandem repeats. The synteny extends beyond the FGF gene
cluster, with FADD (Fadd) located on the FGF3 (Fgf3) side
of the cluster and CCND1 (Ccnd1) located on the FGF19
(Fgf15) side of the cluster. This suggests that the clustering
of the three FGF genes predates the division of the human
and mouse lineages and that the FGF gene cluster may have
arisen by two sequential tandem duplication events from an
ancestral FGF gene. The first duplication may have pro-
duced an FGF19/15 lineage and an FGF3/4 lineage, while
the second duplication may have separated the FGF3 andFGF4 lineages. Thus, FGF19 and FGF15 are homologous,
but there has been more time for the FGF19/15 proteins to
accumulate sequence differences than for the FGF3 and
FGF4 proteins to do so.
FGF15 protein can induce the expression of otic markers in
chick stage 4/5 rostral ectoderm
To determine whether FGF19 and FGF15 have function-
al as well as structural similarity, we assayed the otic-
inducing ability of FGF15. The responding tissue chosen
for this assay was chick stage 4/5 rostral ectoderm, contain-
ing both neural plate and surface ectoderm. This ectoderm
expresses several Wnt genes (Chapman et al., 2004), which
presumably can act in concert with an appropriate exoge-
nous FGF to initiate otic development. As expected from the
previous results of Ladher et al. (2000), beads coated with
human FGF19 protein induced this explanted ectoderm to
express the otic marker, Pax2 (Fig. 2A). To test whether
FGF15 has a similar activity, cells expressing Fgf15 were
tested in the same assay. After culture, the explants
expressed both Pax2 (Figs. 2B,C and Table 1) and Nkx5.1
(Table 1), suggesting that the FGF15-treated ectoderm had
indeed acquired an otic character. A section taken through
Fig. 2. FGF15 is sufficient to induce the expression of Pax2 in chick stripped ectodermal explants. (A) Pax2 expression (purple precipitate) is detected in
stripped ectodermal explants cultured with FGF19-coated beads or (B, C) FGF15-expressing cells. Pax2 expression was assayed after 1 (A, B) or 2 (C) days of
culture. (D) A section through FGF15-expressing cells wrapped in ectoderm reveals expression of Pax2 in the outer layer. (E) Pax2 expression is detected in a
three-layered explant after 2 days of culture (positive control). (F, G) Pax2 expression is not detected at significant levels in untreated stripped ectoderm (F) or
in stripped ectoderm wrapped around untransfected 293 cells (G) and cultured for 1 day (negative controls). Some batches of stripped ectoderm show weak
expression of Pax2 (F), likely due to the presence of contaminating tissues.
T.J. Wright et al. / Developmental Biology 269 (2004) 264–275268an FGF15-induced explant confirmed that Pax2 expression
was confined to the chick tissue outside the layer of 293
cells (Fig. 2D). As expected, a control three-layered tissue
block taken from the rostral region of a stage 4/5 embryo,
which contains the endogenous otic-inducing signals, also
expressed Pax2 (Fig. 2E). Stripped ectoderm cultured in the
absence of additional factors (Fig. 2F) and explant sand-
wiches prepared using untransfected 293 cells (Fig. 2G)
failed to express Pax2, as expected.Pax2 and Nkx5.1 expression were detected in a similar
proportion of explants from the three-layer positive control
and the FGF19-coated beads or the FGF15-expressing cells
combined with stage 4/5 rostral ectoderm (Table 1). Nkx5.1
expression was detected in all of the experimental explants
analyzed and Pax2 expression was detected in approximate-
ly 2/3 of the explants tested. In contrast, half of the stripped
ectodermal explants cultured without additional factors
expressed Nkx5.1 and about 1/3 expressed Pax2. None of
Table 1
FGF15 protein induces the expression of the otic markers Pax2 and Nkx5.1
in chick stage 4 rostral ectoderm
Inducer Responding tissue Genes assayed
Pax2 Nkx5.1
FGF19 beads Ectodermal explant 4/6 9/9
FGF15-expressing cells Ectodermal explant 13/16 9/9
None Three-layer explant 5/8 5/5
None Ectodermal explant 3/16 5/8
Untransfected 293 cells Ectodermal explant 0/3 ND
The numbers in each column labeled with the name of a gene indicate the
number of explants expressing the indicated marker out of the total number
of explants prepared. ND: not done.
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Pax2. It has been observed that a small proportion of
stripped ectodermal explants express otic markers (Ladher
et al., 2000). This background expression is probably due to
the presence of a small amount of contaminating tissue. The
variation in the frequency of background staining between
the marker genes may be due to a differential sensitivity of
these genes to induction by contaminating tissues. Never-
theless, these data show clearly that FGF15 can induce otic
markers in ectodermal explants, suggesting that its activity
is similar to that of FGF19.
Fgf15-deficient mutants have normal otic development at
E9.5–E10.5
Either FGF19 or FGF15 is sufficient to induce the
expression of otic markers in explanted ectoderm, and
FGF signals are clearly required for induction of the otic
placode (Ladher et al., 2000; Leger and Brand, 2002;
Maroon et al., 2002; Phillips et al., 2001; Wright and
Mansour, 2003a). To determine whether Fgf15 is required
for mouse otic development, we generated a mouse strain
carrying a targeted mutation of Fgf15. A genomic DNA
fragment in which a Neo expression cassette oriented in the
antisense direction relative to Fgf15 replaced the entire
coding portion of Fgf15 exon 3 and some 5V flanking
intronic sequences was generated (Fig. 3A). Following
transfection of the targeting vector into mouse embryonic
stem (ES) cells, homologous recombinants were detected by
Southern blot hybridization using 5V and 3V flanking probes
to identify DNA fragments predicted by the targeting
strategy (Figs. 3B,C). Correctly targeted ES cells were used
to generate germline chimeric mice and Fgf15 heterozygous
animals were intercrossed to generate homozygous mutant
embryos of all three possible genotypes (Fig. 3D). Total
RNA isolated from E12.5 wild-type, heterozygous, and
homozygous mutant embryos was analyzed by RT-PCR
using Fgf15 gene-specific primers in exons 2 and 3 flanking
the mutation or in exons 1 and 2, upstream of the disruption.
Products of the expected sizes were generated from the
RNA isolated from wild-type or heterozygous embryos, but
the exon 2/3 product was absent from RNA isolated fromhomozygous mutant embryos (Fig. 3E). The exon 1/2
product was detectable in homozygous mutant RNA, sug-
gesting that transcripts were initiated from the Fgf15 pro-
moter in homozygous mutant embryos. These data confirm
that the targeted insertion in Fgf15 prevents production of
normal Fgf15 transcripts. As the deletion of Fgf15 sequen-
ces removes entirely the exon 3 sequences encoding 1/2 of
FGF15, including most of the residues predicted to be
involved in HSPG and FGFR binding (McWhirter et al.,
1997; Plotnikov et al., 2000; Schlessinger et al., 2000), this
allele is likely to be null.
Heterozygous intercross matings yielded 99 weaned pups
of which 34 were wild type, 62 were heterozygous, and 3
were homozygous mutants, suggesting that Fgf15 is gener-
ally required for viability. The surviving homozygotes
appeared normal and had no difficulties with balance. Two
of these animals were tested for hearing sensitivity and had
normal auditory brainstem responses (data not shown).
Thus, we conclude that the surviving homozygotes repre-
sent ‘‘escapers’’ in which Fgf15 function was compensated
by unknown factors in the genetic background.
To determine whether Fgf15 is required for the early
stages of otic development, we harvested embryos from
heterozygous intercross matings between E9.5 and E12.5.
Of 56 embryos, 9 were wild type, 36 were heterozygous,
and 11 were homozygous mutants. This genotypic distribu-
tion was not significantly different from that expected for an
autosomal recessive mutation, suggesting that the mutation
does not cause lethality before E12.5. The 11 Fgf15/
embryos had no obvious abnormalities and in particular,
their otic vesicles were indistinguishable in whole mount
from those of their wild-type and heterozygous littermates.
To assess more carefully early otic development in homo-
zygous mutant embryos, hematoxylin and eosin-stained
sections of E9.5 wild-type control and Fgf15 homozygous
mutant embryos were compared (Figs. 4A,B). No differ-
ences in the size or position of the otic vesicle were
observed, suggesting that otic induction and otic vesicle
formation occurred normally in the absence of Fgf15.
Patterning of the otic vesicle was analyzed using in situ
hybridization to Pax2. At E10.5, Pax2 transcripts were
detected in the ventro-medial quadrant of the otic vesicle
in both control and mutant embryos (Figs. 4C–F). Further-
more, the location, size, and morphology of the otic
vesicles, which were beginning to develop endolymphatic
ducts dorso-medially and to elongate ventrally, were similar
in both sets of embryos. These data suggest that Fgf15 is not
uniquely required for otic induction, or for the initial
formation and morphogenesis of the otic vesicle.
Mouse Fgf15 transcripts are localized to the neurectoderm,
surface ectoderm, and pharyngeal endoderm during early
otic development
To explore potential explanations of why mouse Fgf15 is
sufficient in the chick explant assay, but not uniquely
Fig. 3. Gene targeting of the Fgf15 locus. Targeting of the Fgf15 gene in mouse ES cells and genotype and RT-PCR analyses of ES cell clones and offspring
from heterozygote intercrosses. (A) The Fgf15 wild-type locus, the targeting vector, and the Fgf15 mutant allele are shown from top to bottom. The targeting
vector carries a replacement of the protein-coding region of exon 3 and flanking intronic sequences with a Neo expression cassette (hatched box, arrow
indicates direction of transcription). Fgf15 exons are numbered and depicted as boxes with untranslated regions shown as open and translated regions shown as
closed. The dotted boxes indicate the locations of the probes used for Southern analysis of gene targeting. Other symbols are as follows: S: SnaBI; R: EcoRV;
X: XbaI; Xh: Xho1; G1, G2, G3: genotyping primers; R1, R2, R3, R4: RT-PCR primers (primer sequences are listed in Materials and methods). (B, C) Southern
blot analysis of genomic DNA isolated from G418-resistant ES cell clones transfected with the targeting vector; correctly targeted recombinants (+/) are
detected using either the 5V probe (B) or the 3V probe (C). Sizes of the bands in kb are indicated to the left of each blot. (D) PCR-based genotype analysis of
Fgf15 alleles present in tail DNAs prepared from Fgf15+/ intercross offspring. Primers G1, G2, and G3 are included in each reaction, giving rise to a band of
500 bp when the wild-type (wt) allele is present and one of 370 bp when the mutant allele (m) is present. (E) RT-PCR analysis of Fgf15 transcripts present in
E12.5 RNAs prepared from Fgf15+/ intercross offspring. The reaction containing primers R1 (exon 2) and R2 (exon 3) gives rise to a band of 984 bp (wt) in
the wild-type and heterozygous samples, but not in the homozygous mutant sample. The reaction containing primers R3 (exon 1) and R4 (exon 2) gives rise to
a band of 166 bp in all three samples with less product evident in the homozygous mutant. Hprt control (c) transcripts are present in each cDNA sample. Fgf15
genotypes are indicated above each lane: / homozygous mutant; +/, heterozygote; +/+, wild type.
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initial development, we analyzed the expression pattern of
Fgf15 during early otic development. Whole-mount RNA in
situ hybridization followed by inspection of cryosections
was used to determine the normal spatio-temporal expres-
sion pattern of mouse Fgf15 between E8 and E10 (Figs.
5A–L). Fgf15 was expressed in the neurectoderm along the
entire rostro-caudal axis, except in the isthmus and in
portions of the diencephalon, and it was detected throughout
the dorso-ventral extent of the neurectoderm in embryos
having as few as 0 somites (Figs. 5A,B) (Gimeno et al.,
2002, 2003; McWhirter et al., 1997). Neurectodermal ex-
pression persisted until at least E10 (Figs. 5C–L), becomingrestricted to a rostrocaudal stripe localized to the middle of
the dorsal–ventral axis. Fgf15 transcripts were also detected
in the surface ectoderm, initiating at or before the 8-somite
stage (Figs. 5G,H) but not earlier than the 5-somite stage
(Figs. 5E,F). These transcripts were localized ventral to the
otic placode and could be detected until the 13-somite stage
(Figs. 5I,J). Fgf15 transcripts were detected in the pharyn-
geal pouch endoderm beginning at the 13-somite stage
(Figs. 5I,J) until at least E10, when transcripts were detected
in the endoderm of the 1st–4th pharyngeal pouches (Figs.
5K,L and data not shown). Additional sites of Fgf15
expression included the tail bud (Fig. 5K), the eye (Figs.
5I,K) (McWhirter et al., 1997), and the primitive streak
Fig. 4. Morphological and in situ hybridization analyses of E9.5–E10.5 Fgf15 mutant embryos reveal no aberrations in the size, location, or patterning of the
otic vesicles. (A, B) Transverse hematoxylin and eosin-stained sections taken from the otic region of E9.5 wild-type (A) and mutant (B) embryos reveal no
differences with respect to the size or position of the otic vesicle. (C–F) As assayed by whole-mount in situ hybridization, expression of Pax2 in E10.5 wild-
type (C) and Fgf15 homozygous mutant (D) embryos is similar. Inspection of transverse sections through the otic region of wild-type (E) and homozygous
mutant (F) embryos shows that loss of Fgf15 has no effect on the normal ventromedial distribution of Pax2. The plane of each section is indicated by a line
through the corresponding whole embryos in panels C and D. Rostral is to the left. nt: neural tube; ov: otic vesicle.
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studies of Fgf15 expression (Gimeno et al., 2002, 2003;
McWhirter et al., 1997).
The expression patterns of chick Fgf19 and mouse Fgf15
have both similarities and differences
In situ hybridization to chick embryos, selected to
match the mouse embryos with respect to developmental
stage, was used to compare the expression patterns of
Fgf19 and Fgf15. Unlike mouse Fgf15 in 0-somite stage
embryos, Fgf19 transcripts at chick stage 5 (before somite
formation) were detected in the mesoderm underlying the
presumptive otic placode (Figs. 6A,B) and also more
caudally in the primitive streak (Fig. 6A). Expression ofFgf19 in the regressing primitive streak continued until at
least stage 11 (12 somites, Figs. 6C–J). At stage 7+ (2
somites), Fgf19 transcripts persisted in the mesoderm
(Figs. 6C,D). Beginning at stage 8+ (5 somites, Figs.
6E,F), expression of Fgf19 was detected in the ventral
neurectoderm as well as the underlying mesoderm; expres-
sion in both these areas was lost at stage 10 (9 somites,
Figs. 6G,H). Fgf19 expression began in the lateral endo-
derm of the foregut at stage 9 (6 somites) (Ladher et al.,
2000). By stage 11 (12 somites), Fgf19 transcripts were
found in the pharyngeal pouch endoderm (Figs. 6I,J) and
by stage 22, transcripts were localized in the endoderm of
the 1st–4th pharyngeal pouches (Figs. 6K,L) similar to the
pattern of expression of mouse Fgf15. At stage 22, Fgf19
transcripts were also present in the optic vesicle, similar to
Fig. 5. Mouse Fgf15 is expressed in neurectoderm, surface ectoderm, and pharyngeal endoderm during early otic development. (A, C, E, G, I, K) Whole
embryos are hybridized with an Fgf15 riboprobe. Each panel indicates the number of somites (s) counted. (B, D, F, H, J, L) A section taken through the otic
region (the plane is indicated by a line through the corresponding whole embryo) is shown in the panel below each whole embryo. Rostral is at the top. Fgf15 is
expressed in the neurectoderm (nf: neural folds; nt: neural tube) at 0 (A, B), 3 (C, D), 5 (E, F), 8 (G, H), and 13 (I, J) somites. Fgf15 expression is also detected
in the surface ectoderm (se) ventral to the otic placode from 8 (G, H) to 13 (I, J) somites. Expression could be found in the pharyngeal endoderm (pe), initiating
at 13 somites (I, J) and continuing at least through E10 (K, L). E10 embryos also show Fgf15 expression in a restricted region of the neurectoderm (K, L), in the
tail bud (tb) (K) and in the optic vesicle (opv) (I, K).
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Unlike mouse Fgf15, Fgf19 transcripts were localized to
the apical ectodermal ridge of the limb buds and in the
condensing VIIIth (vestibuloacoustic) cranial ganglia (Figs.
6K,L). These data suggest that whereas some of the
transcriptional control elements for Fgf15 and Fgf19 have
been conserved, others have diverged over the last 60
million years.Fig. 6. Chick Fgf19 is expressed in the mesoderm underlying the presumptive o
endoderm, and the tail bud. Whole chick embryos are hybridized with an Fgf19 rib
H, J, L). A section taken through the otic region (the plane is indicated by a line t
embryo. Dorsal views (A, C, E, G, I) or lateral views (K) of whole embryos are
embryos are shown in each panel and the somite numbers (s) are shown in br
presumptive otic placode at stage 5 (A, B), stage 7+ (C, D), and 8+ (E, F). Express
until stage 10 (G, H). Additional sites of Fgf19 expression include the endoder
beginning at stage 11 (I, J). At stage 22, Fgf19 expression is detected in the apica
in the pharyngeal pouches, in the optic vesicle (opv), in restricted areas of the brChick Fgfr4 is expressed in both the neurectoderm and
mesoderm during early otic development
In vitro studies have suggested that FGFR4 is the only
FGF receptor that binds to human FGF19 (Xie et al., 1999)
and the crystallographic structure of FGF19 proposes a
rationale for this unusual specificity (Harmer et al., 2004).
Since FGF15 and FGF19 are so closely related, possiblytic placode, the primitive streak, the ventral neurectoderm, the pharyngeal
oprobe (A, C, E, G, I, K) and are sectioned in the transverse plane (B, D, F,
hrough the corresponding embryo) is shown in the panel below each whole
shown with rostral at the top. The Hamilton–Hamburger stages (st) of the
ackets. Fgf19 expression is detected in the mesoderm (m) underlying the
ion in the ventral neurectoderm (nf) is detected beginning at stage 8+ (E, F)
m (e) at stage 10 (G, H) and subsequently the pharyngeal endoderm (pe)
l ectodermal ridge (aer) of the limb buds (K, L). Expression is also detected
ain and in the condensing vestibuloacoustic ganglion (vg) (K, L).
Fig. 7. Chick Fgfr4 is expressed in the mesoderm underlying the
presumptive otic placode and the neurectoderm. Dorsal views of whole
chick embryos hybridized with an Fgfr4 riboprobe (A, C, E) and sectioned
(the plane is indicated by a line through each corresponding whole embryo)
in the transverse plane (B, D, F). The Hamilton–Hamburger stages (st) of
the embryos are shown in each panel and the somite (s) numbers are
indicated where relevant. (A, B) Fgfr4 is expressed in the primitive streak at
stage 3. (C, D) Expression in the mesoderm (m) and the neurectoderm (nf)
is detected at stage 6. (E, F) At stage 8+, Fgfr4 expression in the mesoderm
is reduced but Fgfr4 transcripts persist in the neural tube (nt).
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mouse FGF15. The mouse Fgfr4 gene is expressed exclu-
sively in neurectoderm during early otic development
(Wright et al., 2003). In situ hybridization to chick embryos
was used to determine the expression pattern of chick Fgfr4.
At stage 3, Fgfr4 was detected in the primitive streak (Figs.
7A,B) and this expression persisted until at least stage 6
(Fig. 7C). Similar to Fgf19 transcripts, Fgfr4 transcripts
were detected in the mesoderm at stage 6 (Figs. 7C,D).
Chick Fgfr4 transcripts, however, were also detected in the
neurectoderm at this stage (Figs. 7C,D) and therefore
expression of Fgfr4 precedes the expression of Fgf19 in
this tissue. By stage 8+ (5 somites), overt or strong
expression of Fgfr4 near the presumptive otic placode was
restricted to the neurectoderm (Figs. 7E,F). These data show
that Fgfr4 expression in neurectoderm during the period of
otic induction is similar in mouse and chick, but that chick
has an additional site of Fgfr4 expression in mesoderm.Discussion
The identification of mouse Fgf15 as the structural and
functional homolog of chick Fgf19 and the comparative
analysis of their expression patterns suggest that these genes
may share some common functional roles during early
development. Database searches and protein alignments
revealed chick and human FGF19 as the proteins most
closely related to mouse FGF15. In addition, a syntenicgroup of genes, which includes Fadd, Fgf3, Fgf4, FGF19/
Fgf15, and Ccnd1 is found in both the human and mouse
genomes. Unfortunately, similar comparisons to the chicken
genome are not yet possible. It is notable, however, that the
fgf3– fgf4–ccnd1 gene order is conserved in the zebrafish
genome (http://www.ensembl.org/). In addition, the zebra-
fish FGF19 (Fgf15) ortholog, fgf19, was identified and
mapped between the ccnd1 and fgf4 genes (Katoh, 2003),
suggesting that this particular cluster of FGF-encoding
genes is quite old. The amino acid identity between mouse
Fgf15 and zebrafish fgf19 is 33.5%, which when compared
to the mouse and zebrafish Fgf3 genes (72%) is lower than
expected (Katoh, 2003). Therefore, apparently the Fgf19/
Fgf15 homologs diverged earlier than other FGF homologs.
Despite this coding sequence divergence, FGF19 and
FGF15 share the ability to induce otic genes in explanted
chick ectoderm and their transcripts share some areas of
common expression in mouse and chick, perhaps due to
conserved enhancer/promoter elements. Both Fgf15 and
Fgf19 are expressed in the primitive streak, neurectoderm,
eye, pharyngeal pouches, and tail bud. In the primitive
streak, they are coexpressed with several other members
of the Fgf family, including Fgf8 (Crossley and Martin,
1995). The role of Fgf15 and Fgf19 in the primitive streak
is, however, unknown. Unlike mice lacking Fgf8 (Sun et al.,
1999), Fgf15/ mutants survive beyond gastrulation, sug-
gesting that Fgf15 is not uniquely required in this process.
Similarly, the lack of major anomalies in any organ system
that expresses Fgf15 before E12.5 suggests that either it is
not required or that another member of the Fgf family can
replace its function in these tissues.
Although the expression patterns of Fgf15 and Fgf19
overlap in many places, there are also obvious differences.
In chick, Fgf19 is expressed in the mesoderm underlying the
presumptive otic placode before somite formation (stage 5).
As this tissue is required for otic induction (Baker and
Bronner-Fraser, 2001; Groves, 2004; Kiernan et al., 2002;
Ladher et al., 2000) and FGF19 beads combined with
WNT8C-expressing cells induce cultured chick prospective
otic ectoderm to express otic markers, it was concluded that
Fgf19 is one of the molecules involved in otic induction in
the chick (Ladher et al., 2000). Further assessments of the
requirement for Fgf19 in chick otic induction will require
that this gene be inactivated (or that FGF19 function be
blocked). If, however, otic induction in the chick is similar
to that in mouse and zebrafish, which require redundant
FGF signals (neurectodermal Fgf3 and mesenchymal Fgf10
in mouse and neurectodermal Fgf3 and Fgf8 in fish; Leger
and Brand, 2002; Maroon et al., 2002; Phillips et al., 2001;
Wright and Mansour, 2003a), then the loss of Fgf19
function might not affect otic development unless additional
Fgfs, such as Fgf3 were also eliminated. Indeed, the closest
relative of Fgf19 in the mouse, Fgf15, is clearly not
uniquely required for otic development. In mouse, however,
Fgf15 is never expressed in the mesoderm underlying the
presumptive otic placode, as it is in chick. It is therefore
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during otic induction.
The FGFs signal through a family of tyrosine kinase
receptors, the fibroblast growth factor receptors (FGFRs),
which are encoded by four genes. Tissue-specific alternative
splicing of one exon of Fgfr1, Fgfr2, and Fgfr3 leads to the
production of receptor isoforms with differing ligand bind-
ing specificity and affinity. Structurally related FGF ligands
often have similar receptor binding specificities. For exam-
ple, the closely related family of FGF3, FGF7, and FGF10
all activate FGFR2b most strongly (Igarashi et al., 1998;
Ornitz et al., 1996). In vitro studies suggest that FGFR4 is
the only FGF receptor bound by human FGF19 (Xie et al.,
1999). The proposed crystal structure of FGF19 has features
that distinguish it from other FGFs and suggest mechanisms
for its apparent specificity for FGFR4 (Harmer et al., 2004).
Although the receptor binding and activation properties of
mouse FGF15 are not known, the sequence conservation
with FGF19 and modeling of its structure in relation to that
of FGF19 (Harmer et al., 2004) argue that it may also act
through FGFR4. Because the Fgfr4 null mutant, however,
has no obvious otic abnormalities (Weinstein et al., 1998;
Yu et al., 2000, 2002), it does not shed any light on the
possible functions of mouse Fgf15 in otic development. If
FGFR4 is indeed the receptor for FGF15, then its expression
in the mouse neurectoderm from 0 somites onwards and its
absence from the mesoderm or surface ectoderm would
seem to limit the potential role of FGF15 in mouse otic
induction to an autocrine signal active in the neurectoderm
that might promote expression of the neurectodermal otic
inducer(s) (Wright et al., 2003). Chick Fgfr4 is expressed in
both the neurectoderm and the mesoderm at stage 6. This
suggests that FGF19 may function in either a paracrine
fashion, signaling from the mesoderm to the neurectoderm
or in an autocrine fashion signaling within the mesoderm to
induce or maintain expression of otic-inducing factors. If
FGF15/FGF19 can signal through FGF receptors other than
FGFR4, such as the structurally related ‘‘c’’ isoforms of
FGFR1-3, some of which have been detected in the neu-
rectoderm of both chicks and mice (Orr-Urtreger et al.,
1993, Wright and Schoenwolf unpublished data; Wright and
Mansour, 2003a; Wright et al., 2003; Yamaguchi et al.,
1992), then FGF15/FGF19 signaling scenarios similar to
those proposed above with FGFR4 could be postulated.
Redundant neurectodermal receptors for FGF15 could ex-
plain the absence of otic abnormalities in Fgfr4/ mice.
To determine whether any of the proposed hypotheses for
FGF15/FGF19 signaling during otic induction are valid, it
will be necessary to identify the bona fide in vivo receptors
for both FGF15 and FGF19 and to test genetically or by
knockdown experiments for potential redundancy of these
ligands with other FGFs during otic induction. Based on our
results, we suggest that those FGFs that signal during otic
development to the neurectoderm in mouse and to the
neurectoderm and/or mesoderm in chick are the best poten-
tial candidates for redundancy.Acknowledgments
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